We conducted a phase 2 single-arm nonrandomized controlled trial of lazertinib in patients with EGFR-variant NSCLC with CNS metastases following disease progression after prior first-generation or second-generation EGFR TKIs to evaluate CNS activity, irrespective of presence of the T790M variant. Here, EGFR is linked to non-small cell lung carcinoma.